Immediate Impact
36 standout
Citing Papers
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
2025 Standout
From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
2025 Standout
Works of Setareh Samimi being referenced
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).
2019
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Setareh Samimi | 69 | 29 | 11 | 17 | 8 | 74 | |
| Ana-Maria Mușină | 55 | 17 | 14 | 9 | 10 | 68 | |
| Jill Weiss | 50 | 28 | 5 | 33 | 7 | 63 | |
| W. K. Patterson | 52 | 23 | 4 | 7 | 10 | 74 | |
| Leilana Ly | 52 | 14 | 6 | 12 | 7 | 57 | |
| Susan Preston | 54 | 70 | 33 | 14 | 7 | 89 | |
| Francisco López‐Köstner | 50 | 29 | 11 | 22 | 8 | 74 | |
| Baek‐Yeol Ryoo | 61 | 18 | 8 | 24 | 8 | 79 | |
| Ana Santaballa Bertrán | 30 | 13 | 15 | 15 | 10 | 80 | |
| Piotr Wandzel | 49 | 22 | 10 | 57 | 8 | 92 | |
| Marie Luise Hütter‐Krönke | 51 | 22 | 5 | 9 | 9 | 97 |
All Works
Loading papers...